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Abstract: Rapid eye movement (REM) sleep behavior disorder (RBD) is a parasomnia charac-
terized by a history of recurrent nocturnal dream enactment behavior and loss of skeletal muscle 
atonia and increased phasic muscle activity during REM sleep: REM sleep without atonia. 
RBD and associated comorbidities have recently been identified as one of the most specific and 
potentially sensitive risk factors for later development of any of the alpha-synucleinopathies: 
Parkinson’s disease, dementia with Lewy bodies, and other atypical parkinsonian syndromes. 
Several other sleep-related abnormalities have recently been identified in patients with RBD/
Parkinson’s disease who experience abnormalities in sleep electroencephalographic frequen-
cies, sleep–wake transitions, wake and sleep stability, occurrence and morphology of sleep 
spindles, and electrooculography measures. These findings suggest a gradual involvement of 
the brainstem and other structures, which is in line with the gradual involvement known in these 
disorders. We propose that these findings may help identify biomarkers of individuals at high 
risk of subsequent conversion to parkinsonism.
Keywords: motor control, brain stem, hypothalamus, hypocretin
Introduction
Rapid eye movement (REM) sleep behavior disorder (RBD) is a parasomnia character-
ized by a history of recurrent nocturnal dream enactment behavior and loss of skeletal 
muscle atonia and increased phasic muscle activity during REM sleep: REM sleep 
without atonia (RSWA). RBD was first described in animals by Jouvet in 19651 and 
in humans by Schenck et al in 1986 and Sforza et al in 1988.2–4 RBD is a complex, 
multidimensional parasomnia that is frequently linked with other sleep disorders 
(eg, untreated sleep apnea, narcolepsy with cataplexy of hypocretin-deficient type), 
a wide range of neurodegenerative disorders, and the pharmacotherapy of psychiatric 
and medical disorders (eg, antidepressants, beta-blockers). Imaging studies, clinico-
electrophysiological and experimental models of RBD in cats and rats, and transgenic 
RBD mouse models5 have increased our knowledge of the underlying brainstem 
mechanisms of REM-atonia and REM sleep phasic motor activity. RSWA has been 
closely associated with hypocretin-deficient narcolepsy,6,7 and very strong associations 
have been identified between RBD and the alpha-synucleinopathies, primarily Parkin-
son’s disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy 
(MSA).8–10 Schenck et al were the first to perform a follow-up study and reported that 
38% of their original cohort of 29 patients had developed parkinsonism.11 Twenty years 
after diagnosis, 81% of that cohort had parkinsonism.8 Subsequent studies have reported 
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that approximately half of the patients with idiopathic RBD 
(iRBD) develop a synucleinopathy within ∼12 years of 
diagnosis of RBD.9,10 These studies include highly selected 
patients undergoing full video-polysomnography (PSG) 
recording from neurological sleep centers.
The finding that iRBD often heralds future parkinsonism 
has stimulated research on predictors of imminent parkin-
sonism in RBD. The most elusive goal is to enroll high-risk 
patients in therapeutic studies with promising neuroprotective 
(ie, disease-modifying) agents that could prolong, or ide-
ally halt, the progression of iRBD to clinical parkinsonism/
dementia.
Comorbid findings in RBD
Patients with iRBD typically present with a varying degree of 
nonmotor symptoms, including impaired olfactory function, 
cognitive function,12 and autonomic function determined by 
heart rate changes;13 cardiac 123I-metaiodobenzylguanidine 
(MIBG) uptake reduction;14,15 gastrointestinal abnormali-
ties16; and electroencephalographic slowing.17 Although all 
of these nonmotor symptoms have been associated with par-
kinsonism, each of these symptoms individually has a too low 
specificity and sensitivity of predicting later development of 
parkinsonism. Hyposomnia and constipation, for instance, are 
often observed in the preclinical disease stage, but have a too 
low specificity for predicting PD.18 However, a combination 
of nonmotor symptoms, especially hyposomnia and RBD, has 
been found to increase risk of developing PD.18–20
Nevertheless, these f indings generally support the 
assumption that RBD is part of a general progressive neuro-
degenerative process primarily involving the brainstem area, 
with later involvement of other brain structures.
Neurophysiology of REM sleep
REM sleep is characterized by: 1) tonic components: 
electroencephalogram (EEG), muscle atonia, and loss 
of thermoregulation; and 2) phasic components: REMs, 
muscle twitches occurring against a background of atonia, 
ponto-geniculo-occipital waves, as well as irregularities in 
breathing, heart rate, and blood pressure.
The EEG during REM sleep resembles that during wake-
fulness, which is characterized by low voltage and mixed 
frequency in the cerebral cortex, with 5–9 Hz waves in the 
hippocampus. Therefore, REM sleep is also called as “active” 
or “paradoxical” sleep.
There is sustained low muscle tone during REM sleep in 
most of the somatic muscles except those of the inner ear, eye, 
and diaphragm.21 Cranial muscles of the eyes, ears, and jaw, 
as well as muscles of the limb extremities may show phasic 
twitches/movements against a background of atonia during 
REM sleep. However, phasic activity in postural muscles is 
rarely seen.22
The orchestration of these tonic and phasic REM sleep 
suggests the existence of an “executive mechanism” that 
generates and maintains REM sleep.21,23,24
In the brainstem, there are at least two systems involved 
in wakefulness and nonrapid eye movement (NREM) and 
REM sleep: REM-off and REM-on systems.21,23,24
Neurons belonging to the REM-off system include the 
ventrolateral periaqueductal gray (vlPAG) and the dorsal 
deep mesencephalic reticular nucleus (dDpMe). These nuclei 
are active during wakefulness and NREM sleep, and are 
activated by projections from the wake-active noradrenergic 
locus coeruleus, serotonergic raphe nucleus, and the hypo-
cretinergic neurons from the lateral thalamus. Furthermore, 
the REM-off vlPAG and dDpMe are the only pontomedullary 
structures containing a large number of GABAergic neurons 
projecting to the sublaterodorsal (SLD) nucleus, the struc-
ture critical for generating and maintaining REM sleep.25,26 
When the vlPAG/dDpMe is inhibited by GABAergic projec-
tions from the ventrolateral preoptic nucleus and the lateral 
hypothalamus,23,27 a marked increase in REM sleep is seen 
in rats25 and cats.28,29
The REM-off system has reciprocal interactions with 
the REM-on system, and these two systems mutually inhibit 
each other by means of the neurotransmitter GABA.27 During 
wakefulness and NREM, the REM-off neurons send inhibi-
tory GABAergic projections to structures belonging to the 
REM-on system to prevent the occurrence of REM sleep. 
During REM sleep, the REM-on neurons send inhibitory 
GABAergic/glycinergic projections to structures belonging 
to the REM-off system.30
Neurons in the caudal laterodorsal tegmental nucleus 
(cLDT) and SLD (cLDT-SLD) are regarded as critical sites 
for the generation and maintenance of REM sleep, the 
“executive mechanism”.5,31,32 These neurons activate the 
precoeruleus and parabrachial nucleus, which are involved in 
REM-EEG. In addition, the ventral part of the SLD induces 
sensory inhibition and motor atonia during REM sleep. The 
SLD contains glutamatergic neurons that directly project to 
inhibitory interneurons in lamina VIII of the spinal cord and 
to nuclei, inducing atonia in the ventromedial medulla.27,33 In 
turn, the spinal interneurons and the ventromedial medulla 
project GABA
A/B/
glycine to the spinal and cranial motoneu-
rons, thereby hyperpolarizing the motor-facilitatory neurons 
and inducing atonia.5,27,31,34,35 Nuclei in the ventromedial 
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medulla, belonging to the REM-on system, include the 
magno cellular reticular nucleus, gigantocellular nucleus 
(GiA, GiV), paragigantocellular nucleus (DPGi, LPGi), 
parvicellular nucleus, and the raphe magnus.26,31,36
Lesions of the SLD, such as a deletion of the Vglut2 
in the cLDT-SLD, result in REM fragmentation, which is 
characterized by reductions in REM sleep epoch duration 
and an increase in the number of REM episodes. The SLD 
has direct projections to lamina VIII in the spinal cord, where 
they excite GABA/glycinergic interneurons. Elimination of 
GABA/glycinergic transmission from these interneurons in 
the ventral horn at the C3–C4 level in mice results in brief 
twitching and jerking movements, predominantly in the upper 
body and sporadically in the lower body.37 In addition, lesions 
of the SLD result in complex behaviors during REM sleep, 
symptoms consistent with the human syndrome of RBD.27 
Therefore, it has been hypothesized that the SLD specifi-
cally functions to antagonize the phasic activity of postural 
muscles of complex behaviors driven by the motor cortex.38 In 
contrast, cell-body lesions of the ventromedial medulla seem 
to cause simple behaviors, such as rapid phasic jerking and 
twitching movements, during REM sleep in rats and cats.39,40 
However, more complex behaviors, as seen with lesions of the 
SLD, are not observed. Therefore, the ventromedial medulla 
only partially mediates the SLD control of REM atonia.
Recent findings have revealed that glutamatergic neurons 
in the rostral parvocellular reticular formation are critical for 
phasic masseter activity during REM sleep.41
As SLD lesions apparently do not affect phasic masseter 
activity during REM sleep,41 it was hypothesized that the 
SLD is not the generator of phasic activity in this muscle 
and that it specifically antagonizes the complex activity 
of postural muscles driven by the motor cortex and simple 
behaviors controlled by the ventromedial medulla–spinal 
projections.38
Brainstem areas other than the SLD and the ventrome-
dial medulla may be involved in the control of REM atonia. 
A study performed by Lai et al reported that lesions in the 
mesopontine junction cause periodic limb movements during 
REM sleep in cats.42 In addition to glutamate and GABA/
glycine, other neurotransmitter systems may mediate REM 
atonia, by direct projections to the spinal cord or by acting 
on the vlPAG matter, lateral pontine tegmentum, SLD, or 
ventromedial medulla neurons, including monoaminergic, 
orexinergic, and melanin-concentrating hormones.33,43–45 
In summary, animal studies indicate that the SLD is the 
critical region for the control of REM atonia, and lesions 
of the SLD give rise to the full phenotype of RBD, whereas 
lesions to the ventromedial medulla produce muscle jerks 
and twitches.
The occurrence of RBD is consistent with the findings 
of a study in 2003 by Braak et al,46 who described a staging 
system for the neuropathological development of PD. The 
aggregation of Lewy bodies is hypothesized to arise from the 
dorsal motor nucleus of the vagal nerve in the medulla and 
in the olfactory bulb, and to emerge through the coeruleus/
subcoeruleus complex and the magnocellularis reticular 
nucleus until it involves the substantia nigra, which has 
been associated with the daytime motor symptoms of PD. 
Neuropathological studies of iRBD reveal the presence of 
Lewy bodies in the brain.47
Generally, the staging suggests that the accumulation 
of aggregated intracytoplasmic proteins has a general dis-
tribution, primarily including the upper area of the medulla 
oblongata and lower brainstem region with progressive 
involvement of other parts of the brainstem and midbrain. The 
joint involvement of the olfactory area suggests that specific 
parts of the brain are more prone to this, but the specific 
mechanism is not known in detail. The spreading pattern 
partly explains the progressive distribution of the involvement 
of nonmotor symptoms and other characteristics, eg, initial 
gastrointestinal symptoms (vagal nuclei/autonomic function) 
and loss of REM atonia (SLD nuclei).48 The picture of neu-
ropathological spreading of Lewy bodies is probably more 
complex, as not all diagnosed PD patients have a history of 
recurrent dream enactment behavior and RBD and as other 
nonmotor symptoms occur with varying intensities prior to 
and in PD and other alpha-synucleinopathies.
RBD diagnosis
According to the third edition of the International Classifi-
cation of Sleep Disorders (2012), the following criteria are 
required to make a diagnosis of RBD:
1. Repeated episodes of sleep-related vocalization and/or 
complex motor behaviors;
2. These behaviors are documented by PSG to occur during 
REM sleep, or based on clinical history of dream enact-
ment, and are presumed to occur during REM sleep;
3. Polysomnographic recordings demonstrating RSWA; 
and
4. The disturbance not better explained as another sleep 
disorder, mental disorder, medication, or substance use.
According to the American Academy of Sleep Medicine, 
RSWA is defined by sustained muscle activity in REM sleep 
(Stage R) with 50% of the epoch having increased chin elec-
tromyography (EMG) amplitude, and/or excessive transient 
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muscle activity, defined by the presence of five or more 
mini-epochs (a 30-second epoch is divided into ten 3-second 
mini-epochs) in an epoch featuring transient muscle activity 
lasting at least 0.5 seconds.22
A diagnosis of RBD cannot be made unless dream enact-
ment and RSWA are both present, so a PSG is required to 
make the diagnosis. RBD has a wide spectrum of overt 
symptoms, such as twitching, jerking, shouting, and scream-
ing, as well as more complex behaviors, including punching 
and escape behaviors, that may cause harm to some patients 
or bedpartners. The simultaneous video-PSG recording is 
essential for evaluating these movements and vocalizations 
appearing during REM sleep and to discount the presence 
of epileptiform activity in the EEG derivations in order to 
make a diagnosis of RBD.49
While violent and complex dream enactment behavior is 
rarely observed during a single night’s PSG recordings, an 
abnormal state of increased EMG tone during REM sleep 
and sparse limb jerks are common events.
Polysomnographic findings in RBD
PSG consists of a comprehensive and simultaneous recording 
of various body functions, including brain activity (electro-
encephalogram [EEG]), eye movements (electrooculography 
[EOG]), muscle activity (electromyogram [EMG]), and heart 
rhythm (electrocardiogram [ECG]) during sleep. Several 
studies have evaluated the involvement of different PSG 
findings. These abnormalities are presented later. A sche-
matic representation of these PSG abnormalities and their 
potential neurophysiological and neuroanatomical findings 
is presented in Figure 1.
Scoring RBD
Lapierre and Montplaisir were the f irst to present an 
objective scoring method, based on visual analysis of PSG 
studies.50 Since this initial description of RSWA, several 
methods for scoring of RBD have been proposed, analyzing 
RSWA with semiautomated or fully automated algorithms. 
Frauscher et al suggested a PSG montage quantifying 
“any” EMG activity (tonic, phasic, or both) in the mentalis 
muscle and phasic EMG activity in the right and left flexor 
digitorum superficialis muscles in the upper limbs, with a 
cutoff of 32% (when using 3-second mini-epochs) for the 
diagnosis of RBD.51 Ferri et al measured the amplitude of 
the submentalis muscle during sleep in 21 patients with 
iRBD, ten patients with MSA, and ten healthy controls, 
and provided practical indices for the objective evaluation 
of EMG atonia and EMG activations by means of a sleep 
atonia index.52 A subsequent study by Montplaisir et al53 
attempted to identify cutoff values for tonic and phasic EMG 
activity in submentalis muscle and to assess the sensitivity 
and specificity of these values, taken separately or in com-
bination, to diagnose patients with iRBD. They studied 
80 patients with iRBD and 80 age- and sex-matched controls. 
Tonic and phasic EMG activities were visually identified in 
the chin, but not in the limbs. Completely correct classifica-
tion of 81.9% was found for tonic chin EMG density $30%; 
83.8% for phasic chin EMG density $15%, and 75.6% for 
$24 leg movements/hour of REM sleep. Another study by 
Frandsen et al defined a method for establishing a baseline in 
automatic quantifying submental motor activity during REM 
sleep in iRBD, PD, and controls.54 They found that no control 
had .30% of REM sleep with increased motor activity. How-
ever, patients with known RBD had activity as low as 4.5%. 
There is currently no comparison between the two methods, 
especially with respect to emphasizing the accuracy and the 
association with later neurodegenerative development.
The studies differ in their methods and definition of 
RBD EMG activity in the separation between patients with 
(i)RBD and healthy controls. Some studies differentiate 
between tonic and phasic EMG activity and use 20-second 
epochs for tonic and 2-second epochs for phasic,53 whereas 
others have included any EMG activity but use different 
methods to analyze EMG activity, either by separating sleep 
into 30-second and 3-second epochs51 or by distinguishing it 
from the background EMG activity.54 Although there is con-
sensus that brief bursts of EMG activity and muscle twitches 
are phasic events, the challenge arises as to how to classify 
more complex behavioral events, such as a patient with RBD 
defending himself. It is possible that the difference between 
tonic and phasic may be more quantitative than qualitative, 
as suggested by Ramaligam et al, who proposed that the 
phasic movements are disinhibited in humans with RBD 
and that RBD results more from failure of the suppression 
of phasic activity of postural muscles than from dysfunction 
of tonic control.38 Other studies identified RSWA using the 
EEG and EOG channels for REM sleep detection, while the 
abnormally high muscle activity was detected from the EMG 
channels, and the submental was combined with the left and 
right anterior tibialis. RSWA was identified by considering 
it as an outlier problem, in which the number of outliers 
during REM sleep was used as a quantitative measure of 
muscle activity.55 There is no consensus in the medical lit-
erature about the scoring of EMG activity in iRBD, which 
suggests that a task-force is needed, especially as studies are 
beginning to focus on the role of RSWA without subjective 
complaints of dream-enactment behavior as a subclinical 
symptom of iRBD.
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Neurons involved Electrophysiological
 patterns
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EOG: Left and right
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EOG: Left and right
EEG: All derivations
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W
REM
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Rapid eye movements
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(REM-on)
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Oculomotor
 nucleus
Prepositus
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(REM-of) SLD/PC
(REM-on)
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(Sleep-on)
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(Sleep-off)
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(Sleep-off)
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Pyramidal cortical
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(Sleep-on)
LDT/PPT
(Sleep-off)
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vPAG/TMN
(Sleep-off)
Thalamus
Thalamus
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Figure 1 examples of potential PD biomarkers expressed in polysomnographic signals and their neuroanatomical correlates.
Notes: Sleep is mainly controlled by two mutually dependent neuronal control loops illustrated by blue (wake–sleep) and red (ReM–NReM). Disruption in any of these 
may be expressed electrophysiologically in the eeG, eOG, or eMG or in the hypnogram. During ReM sleep, a descending branch of neurons from the SLD projects into 
medullary premotor neurons generating atonia, which electrophysiologically can be measured in the eMG and eOG signals. An ascending branch of neurons from the 
SLD projects into rostral brain areas responsible for the cortical activation during ReM sleep, expressed electrophysiologically in the eeG as, eg, sawtooth waves. During 
ReM sleep, characteristic ReMs controlled by the saccadic control mechanisms are expressed in the eOG signals. During NReM sleep, the sleep promoting pathway 
inhibits the ascending arousal pathways introducing slowing of the EEG as well as sleep-specific events expressed electrophysiologically in the EEG as, eg, delta waves 
or sleep spindles. in all these examples, the involved neurons can be vulnerable to early neurodegeneration as seen in PD and can thus serve as electrophysiological PD 
biomarkers.
Abbreviations: PD, Parkinson’s disease; ReM, rapid eye movement; NReM, nonrapid eye movement; eeG; electroencephalogram; eOG, electrooculography; eMG, 
electromyography; SLD, sublaterodorsal region; vLPO/MnPO, ventrolateral/median preoptic nucleus; LDT, laterodorsal tegmental nucleus; PPT, pedunculopontine tegmental 
nucleus; LC, locus coeruleus; PC, precoeruleus area; DR, dorsal raphe nucleus; vPAG, ventral periaqueductal gray; TMN, tuberomammillary nucleus; vlPAG, ventrolateral 
periaqueductal gray matter; LPT, lateral pontine tegmentum; BF, basal forebrain.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
111
Neurophysiology of ReM sleep
 
N
at
ur
e 
an
d 
Sc
ie
nc
e 
of
 S
le
ep
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
22
5.
17
8.
2 
on
 1
0-
Ju
n-
20
17
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Nature and Science of Sleep 2016:8submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
112
Jennum et al
Is RSWA a marker for RBD?
In 2015, Stefani et al reported results of a follow-up study 
of subjects with isolated RSWA without dream enactment.56 
After a mean of 8.6 years (SD =0.9), one of 14 participating 
subjects (7.3%) had progressed to RBD. Ten of 14 RSWA 
subjects (71.4%) were positive for at least one neurode-
generative biomarker. Substantia nigra hyperechogenicity 
and the presence of mild cognitive impairment (MCI) were 
both present in four of 14 subjects with isolated RSWA. 
Electromyographic activity measures increased significantly 
from baseline to follow-up PSG (any mentalis and both ante-
rior tibialis muscles). The authors concluded that isolated 
RSWA may be an early biomarker of synuclein-mediated 
neurodegeneration.
A recent study reported the prevalence of iRBD to be 
2.01% and subclinical RBD (ie, patients with isolated RSWA 
without dream enactment behavior) to be 4.95% in elderly 
Koreans.57 Whether RSWA without dream enactment is in 
fact a marker and comparable and as such a potential marker 
for later neurodegenerative conversion is not resolved and 
needs additional electrophysiological, clinical, and follow-
up studies.
Periodic limb movements in RBD
Few studies have investigated the clinical significance of peri-
odic leg movements of sleep (PLMS) in patients with RBD 
and the pathological association between these disorders. 
A high prevalence of PLMS is observed in patients with PD 
as well as with atypical parkinsonism.58 The occurrence of 
PLMS has been associated with the dopaminergic system, 
and the first-line treatment of idiopathic PLMS consists 
of dopaminergic medications, the same as in PD. In addi-
tion, studies with positron emission tomography (PET) and 
SPECT imaging suggest that sleep abnormalities in PD, 
including an increased prevalence of PLMS, are indirect 
manifestations of the primary striatal dopamine deficiency.59 
Happe et al reported a negative correlation of PLMS and 
striatal [123I]β-CIT SPECT binding in patients with PD, 
which supports the hypothesis that the occurrence of exces-
sive nocturnal movements in PD is dependent on the severity 
of the presynaptic dopaminergic dysfunction.60 Sasai et al 
compared iRBD patients with and without PLMS. RSWA/
REM was found to be a factor significantly associated with 
the existence of PLMS during NREM and REM stages, but 
the duration of RBD morbidity was associated with PLMS 
only during the REM stage.61 Whether PLMS during REM 
sleep in iRBD involves the same structures mediating atonia 
needs to be explored further.
REMs during REM sleep
Electrolytic lesions of the pedunculopontine tegmental 
nucleus (PPT) reduce the phasic activity of eye movements 
and other phasic REM features in cats (Figure 1).62 Although 
this study did not determine which type of neurotransmit-
ter (cholinergic or glutamatergic) is involved in REMs, it 
demonstrated that the PPT and surrounding regions contain 
the generators of REMs.62 A clinical study applying video-
oculography in patients with clinically probable RBD showed 
that ∼24% of these patients have abnormal eye movements 
compared with only 7% of patients without clinically the 
condition,63 suggesting brainstem or cerebellar dysfunction. 
This confirms the results of other studies that analyzed eye 
movements during REM sleep in iRBD and PD using an 
automatic algorithm.64
EEG-slowing
Animal studies have implicated the reciprocal projections 
between the glutamatergic projections of the SLD and the 
cholinergic projections of the PPN/LDT in initiating REM 
sleep. It is known that these structures initiate ponto-geniculo-
occipital waves, which involve distinct cortical areas 
(Figure 1). Several studies have reported that patients with 
iRBD present with a slowing of the EEG during wakefulness 
and REM sleep. Fantini et al were the first to analyze the 
EEG in iRBD by doing a quantitative EEG analysis during 
wakefulness and REM sleep. In their study, patients with 
iRBD showed considerably higher theta power in frontal, 
temporal, and occipital regions, with lower beta power in the 
occipital region. During REM sleep, the patients with iRBD 
presented with lower beta power in the occipital regions than 
in controls, although the sleep architecture was similar in the 
two groups. They suggested that their results reflect an early 
sign of impaired cortical activity.65 In a subsequent study, 
Massicotte-Marquez et al obtained similar results from ana-
lyzing EEG recordings during wakefulness in patients with 
iRBD and controls.66 They reported higher delta and theta 
power in iRBD during wakefulness in all brain areas compared 
with controls. These results are in line with imaging studies 
showing decreased blood flow in the frontal, temporal, and 
parietal lobes in patients with iRBD.67 Moreover, Iranzo et al 
evaluated spectral power EEG activity during both wakeful-
ness and REM sleep in iRBD subjects who later developed 
MCI, a transitional stage between normal cognitive function 
and dementia.68 They analyzed the right and left hemispheres 
and found that increased delta and theta activity was more 
marked in the central than in the occipital region and in the 
right than in the left hemisphere. Moreover, they observed 
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that patients who went on to develop MCI had more severe 
EEG-slowing than those patients with iRBD who remained 
idiopathic. A subsequent study have confirmed the relation 
between EEG-slowing and the occurrence of MCI.69
The EEG spectral pattern of patients with iRBD, who 
developed MCI, as well as the cortical hypoperfusion, cor-
responds to the observations in early stage PD and DLB.70,71 
Cortical EEG-slowing and the cognitive impairment 
occurring in patients with iRBD may be caused by damage 
of the brainstem structures that regulate REM sleep and 
activity in the neocortex.
On the other hand, NREM sleep does not seem to be 
affected. Latreille et al investigated slow wave characteris-
tics in iRBD and controls based on automatic slow wave 
detection. They measured the slow wave density, amplitude, 
frequency, slope, and duration of negative and positive 
phases and found similar results in patients with iRBD and 
controls. They concluded that the level of synchronization 
of thalamocortical neurons during NREM sleep was similar 
in both groups.72
Sleep spindles
Changes have been reported in relation to the microstructure 
of sleep, especially in relation to sleep spindles. Christensen 
et al assessed sleep spindles in patients with iRBD, PD 
patients with RBD, PD patients without RBD, and controls. 
They measured the density of sleep spindles with an auto-
matic algorithm in REM and NREM sleep, and found that 
patients with iRBD and PD patients with and without RBD 
had a markedly lower density of sleep spindles in NREM 
than did controls.73 They suggested that the lower density in 
sleep spindles in these patients might involve dysfunction 
in prethalamic fibers in alpha-synucleinopathies. However, 
in another study based on manually identified spindles, they 
found no association in PD patients between spindle density 
or morphology and disease duration or severity.74
Several studies suggest that sleep spindles and slow waves 
play a role in brain plasticity and are associated with cogni-
tive function. Latreille et al investigated whether alterations 
in sleep spindles and slow waves at the baseline visit could 
predict development of dementia at follow-up in PD.75 They 
investigated 68 nondemented PD patients and 47 healthy 
controls with baseline-PSG and comprehensive neuropsy-
chological assessment. Sleep spindles and slow waves were 
automatically detected during NREM sleep throughout the 
entire night. At follow-up, an average of 4.5 years later, 18 PD 
patients had developed dementia and 50 remained dementia 
free. Sleep spindle density and amplitude were lower in 
PD patients who converted to dementia compared with the 
patients who remained dementia free and controls, mostly in 
posterior cortical regions. Dementia-free PD patients were 
intermediate between dementia patients and controls, with 
lower baseline sleep spindle density in all cortical areas 
compared with controls. Moreover, the authors found that 
in demented PD patients, lower sleep spindle amplitude 
in parietal and occipital areas was associated with poorer 
visuospatial abilities. Although slow wave amplitude was 
lower in PD patients than in controls, no difference was 
observed between those who developed or did not develop 
dementia.
The aforementioned results demonstrate that there are 
NREM sleep EEG abnormalities in PD patients. Sleep spindle 
activity was particularly impaired in PD patients who devel-
oped dementia, with a more posterior topographic pattern. 
Sleep spindle alterations are associated with later develop-
ment of dementia in PD, and thus, may serve as an additional 
marker of cognitive decline in these patients.
Sleep instability
The SLD is critical for inducing cortical activation and atonia 
during REM sleep. Although lesions of the SLD induce the 
RBD-like phenotype in rats, they do not seem to affect REM 
sleep time and sleep transitions.27 Instead, lesions involving 
the caudal part of the LDT, which lies dorsal to the SLD, 
lead to severe sleep fragmentation involving both REM and 
NREM sleep, and reduction in the amount of REM sleep.27 
Sleep-wake fragmentation and reduction in REM sleep have 
also been reported in mice with lesions of the glutamatergic 
neurotransmission in this area and after large lesions of the 
PPT-LDT and SLD in cats.37,76 As the brainstem is affected in 
the early stages of the PD disease process,77 this may explain 
the sleep fragmentation seen in this disorder. Christensen 
et al evaluated sleep characteristics such as sleep stability 
and sleep transitions in patients with iRBD and PD.78 They 
determined the transitions and the stability measures based 
on the manually scored hypnogram as well as by a data-
driven method. They found that the patients had less stable 
REM and NREM sleep, and more REM/NREM transitions 
than controls, and suggested that these are affected in iRBD 
and PD.78
Pathophysiologically, sleep fragmentation and abnormali-
ties in sleep architecture in PD might originate from nocturnal 
motor phenomena, such as increased muscle tone, akinesia 
or tremor, or drug side-effects. Since iRBD is considered as 
a premotor stage to alpha-synucleinopathies, these motor 
phenomena do not occur, and hence, this instability may be 
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explained by the neurodegenerative process itself, which 
involves the neurochemical systems responsible for sleep 
organization.
Heart rate variability
Lanfranchi et al studied heart rate variability (HRV) during 
REM and NREM sleep in ten patients with iRBD and found 
that differences normally observed between these sleep stages 
were not present in patients with iRBD, indicating a loss of 
cardiac autonomic innervation.79 Sorensen et al investigated 
heart rate response in relation to arousals and leg movements 
during sleep in eleven patients with iRBD, 14 PD patients 
with RBD, 16 PD patients without RBD, and 17 controls, 
and found a significantly lower heart rate response to leg 
movements, whereby the heart rate response in iRBD was 
intermediate with respect to the control and the parkinsonian 
groups.80
Cardiac function in iRBD has also been measured during 
waking ECG. A study by Valappil et al measured ECG during 
wakefulness in eleven patients with iRBD and eleven control 
subjects with idiopathic insomnia without RBD. HRV was 
determined from 5-minute segments of a single-channel ECG 
during PSG evaluations, using automatically detected R–R 
intervals during wakefulness. The authors were able to cor-
rectly classify 77.3% of subjects using discriminant analysis 
featuring the leave-one-out cross-validation method and sug-
gested that HRV measured by routine ECGs could be used to 
screen for Lewy body disorders such as PD.81 These findings 
are in agreement with studies showing decreased cardiac 
autonomic dysfunction by means of MIBG-scanning.
Miyamoto et al used 123I-MIBG cardiac scintigraphy to 
investigate cardiac sympathetic denervation in patients with 
iRBD and observed reduced uptake in all 13 patients.82 These 
changes were also found in patients with PD and DLB,15 
adding to the evidence supporting the hypothesis that iRBD 
is part of a continuum including PD and DLB.
Although cardiac denervation is shown in iRBD and in 
PD, the course of cardiac denervation over time seems to be 
heterogeneous and independent of the development of motor 
symptoms.83,84 Postuma et al analyzed PSG trace measures of 
beat-to-beat R–R variability in 21 patients with iRBD who 
developed neurodegenerative disease, including PD (eleven 
patients), MSA (one patient), and dementia (nine patients). 
They found that despite clear differences between patients 
with iRBD and controls, there were none for any measure 
between those who did or did not develop disease.85
The results from these studies suggest that HRV during 
both wakefulness and sleep is lower in patients with iRBD 
compared with control subjects, suggesting abnormalities 
of sympathetic and parasympathetic functions. Cardiac 
autonomic dysfunction is also impaired in PD, suggesting 
that impaired HRV may be an early sign of PD.
Brainstem reflexes
As the pathophysiology of RBD involves dysfunction of 
brainstem structures, neurophysiological investigation of 
brainstem reflexes may reveal abnormalities in patients with 
alpha-synucleinopathies presenting with RBD. The electric 
blink reflex is a neurophysiological technique measuring 
brainstem function through a reflex arc involving the fifth to 
seventh cranial nerves.86 Besides the trigeminofacial reflex 
arc, this reflex involves the brainstem reticular formation. 
Several investigations of the blink reflex have been performed 
in patients with neurodegenerative disorders. In patients with 
DLB, the electric blink reflex latency is delayed relative to 
controls, independent of the presence of RBD. The amplitude 
of the auditory blink reflex has been found to be normal in 
patients with MSA.87 However, these patients present with an 
exaggerated startle response based on the other muscles Kofler 
et al investigated.88 Abnormal startle responses have also been 
found in other parkinsonian disorders, including DLB.88 
A case report of a patient with RBD had concurrent exces-
sive startle response to visual stimuli,89 probably caused by a 
pontine lesion and subsequent affection of the bulbopontine 
reticular formation. Other methods have documented the 
involvement of brainstem. Zoetmulder et al evaluated the 
use of prepulse inhibition90,91 and found that the sensorimo-
tor gating, as measured with prepulse inhibition, is markedly 
reduced in patients with MSA but not in patients with iRBD 
or PD, suggesting that striatal and brainstem dysfunction is 
more severely affected in these patients. There are, however, 
limited data relating to this topic.
Imaging
Functional imaging techniques, such as SPECT and PET, 
have been used in an attempt to detect abnormal functional 
alterations in patients with RBD predicting evolution toward 
the onset of alpha-synucleinopathies. A reduced striatal bind-
ing of radioligands, such as 123I-FP-CIT and 11C-DTBZ, 
has revealed subclinical nigrostriatal dopaminergic degenera-
tion in patients with RBD before the appearance of PD.92–95 
Iranzo et al96 reported that in patients with iRBD, serial (123) 
FP-CIT SPECT shows a decline in striatal tracer uptake that 
reflects progressive nigrostriatal dopaminergic dysfunc-
tion. The mean reduction in striatal (123) FP-CIT uptake 
from baseline to 3 years was 19.36% in the right putamen, 
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15.57% in the left putamen, 10.81% in the left caudate, and 
7.14% in the right caudate. They suggested that serial (123) 
FP-CIT SPECT can be used to monitor the progression of 
nigrostriatal degeneration in iRBD and could be useful in 
studying the potential disease-modifying compounds in 
these patients. A 6-[18F]fluoro-l-dopa PET study assessing 
the rate of disease progression in PD scanning patients twice 
with a 5-year interval suggested that the disease process first 
affects the posterior putamen, followed by the anterior puta-
men and caudate nucleus.97 Brain imaging of iRBD patients 
with PET showed lower levels of dopamine transporters in 
the nigrostriatal pathways that further decreased over time 
until reaching the level when parkinsonism appeared.98 It is 
not clear to what extent the nigrostriatal dopamine system is 
directly associated with increased motor activity during REM 
sleep. A (123) FP-CIT SPECT by Eisensehr et al95 reported 
that muscle activity during REM sleep lasting persistently 
longer than 0.5 seconds was independently associated with 
reduction of striatal dopamine transporters. However, these 
results could not be reproduced in a subsequent (123) FP-CIT 
SPECT study by Kim et al,99 which indicates that this topic 
needs more investigation.
In addition to SPECT and PET scanning, imaging apply-
ing combined neuromelanin-sensitive, structural, and diffu-
sion magnetic resonance imaging at 3T in PD patients with 
and without RBD showed a relationship between damage 
to the locus subcoeruleus and abnormal muscle tone during 
REM sleep.100
Imaging with [18F]-fluorodeoxyglucose PET in iRBD 
revealed a higher metabolic rate in the hippocampus/
parahippocampus, cingulate, supplementary motor area, and 
pons, but a lower rate in the occipital cortex/lingual gyrus.101 
This suggests that region-specific metabolic abnormalities 
exist in patients with RBD and regional metabolic activities 
are associated with clinical measures such as RBD duration 
and chin EMG activity. Few studies have investigated the 
brain regions that are active during RBD.
An investigation applying ictal SPECT with simulta-
neous PSG recordings showed increased perfusion in the 
supplementary motor area during a REM sleep behavior 
episode.102 These findings were confirmed in a subsequent 
study using ictal SPECT and simultaneous PSG reporting 
bilateral activation of the premotor (supplementary motor) 
areas, the interhemispheric cleft, the periaqueductal area, 
the dorsal and ventral pons, and the anterior lobe of the 
cerebellum in the four patients examined.103 These studies 
suggest a common motor pathway in RBD and localize the 
motor generators responsible for dream enactment behavior 
to include the supplementary motor pathway bypassing 
the basal ganglia. These findings confirm a previous study 
reporting the “normalization” of movements during REM 
sleep in patients with RBD, which suggests that the move-
ments during RBD could be generated by the motor cortex 
and would involve the pyramidal tract bypassing the extrapy-
ramidal system.104
Biomarkers
According to Stern, preclinical PD is suspected when genetic, 
molecular, or imaging biomarkers support the presence of 
PD-specific pathology, but when no clinical signs and symp-
toms are yet evident.105 However, identifying PD patients 
in the preclinical stage is very challenging.3 Premotor PD 
is defined by the presence of early nonmotor signs and 
symptoms due to extranigral PD pathology.3,49 On account 
of this, the challenge is to identify reliable biomarkers to 
confirm the diagnosis of premotor PD. Several biomarkers 
have already been identified in the preclinical stage of PD, 
including RBD, hyposmia, MCI, autonomic dysfunction, 
and imaging. However, it is still a matter of debate which 
combination of screening tests is most sensitive to predict 
conversion from iRBD to PD.
Moreover, there is limited data concerning the identifi-
cation of molecular markers in RBD. In one study, elevated 
alpha-synuclein levels in cerebrospinal fluid and serum 
were suggested to correlate with probable RBD, but the 
presence of RSWA was not documented by video-PSG. As 
iRBD is a strong predictor of the later development of an 
alpha-synucleinopathy, the development of alpha-synuclein 
ligands used in imaging and the development of drugs 
antagonizing this protein should receive more focus. There 
are limited data regarding other neurodegenerative biomark-
ers, eg, Tau protein (t-Tau), phosphorylated Tau (p-Tau
181
) 
protein, α-synuclein, neurofilament light, and chitinase-3-
like protein-1, also known as YKL-40. The inflammatory 
marker YKL-40 has been found to be lower in PD and 
atypical PD,106,107 whereas other studies have only found 
elevated levels in AD but not PD.108 RSWA/RBD is strongly 
associated with hypocretin-deficient narcolepsy type 1,7 but 
in nonnarcoleptic RBD and in LBD, hypocretin levels were 
found to be normal.109,110 However, this does not imply that the 
hypocretin system is not involved in the neurodegenerative 
process as a lower frequency of neurons has been identified 
in PD patients;111,112 the cerebrospinal fluid (CSF)-hcrt-1 level 
reflects the general cerebrospinal level, and it is likely that the 
CSF concentration may be normal or subnormal, despite the 
significant loss of hypothalamic hypocretinergic neurons.
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Treatment of RBD episodes
The medical literature on the treatment of RBD reflects a lack 
of randomized, double-blind controlled trials. Clonazepam 
and melatonin have been the most commonly used drugs 
for the nocturnal treatment of RBD. The use of these drugs 
is justified on the basis of small case series,113 and a small 
controlled trial has been conducted only for melatonin,114 in 
which only a limited effect was proved. Studies have most 
frequently focused on clonazepam. However, side effects 
may limit the use of clonazepam, especially in elderly and 
demented patients.113 A single case report has been presented 
regarding the positive effect of hypnotics and sodium oxy-
bate,115,116 but its findings are very limited. In addition, there is 
little information about the efficacy of medication for RBD in 
narcolepsy type 1. We also know little about other drugs.
The effect of antidepressants (SSRI, TCA) and sodium oxy-
bate on RBD varies from positive to negative,117 although the 
evidence is limited. As depression is associated with RBD, it is 
a strong confounder. Future studies need to address the effect 
of medications on outcome measures such as the improvement 
of the PSG features of RBD including RSWA, improvement 
of the quality of sleep, and prevention of injury.
In PD, a number of pathways and mechanisms have 
been the target for pharmacological intervention, including 
mitochondrial dysfunction, oxidative stress, inflammation, 
protein handling, and prion-like processes.118 However, none 
of these interventions appear to be effective in delaying the 
disease process in PD.119 Therefore, increased understanding 
about the pathophysiological mechanism in both iRBD and 
PD is necessary to be able to develop effective treatment 
regimens. As follow-up studies have convincingly shown 
that iRBD is a strong marker for later development of an 
alpha-synucleinopathy, patients with iRBD may be enrolled 
in future neuroprotective pharmacological studies.
Physical activity, physiotherapy, and social activities have 
been shown to modify the symptoms of PD.120–122 However, 
there are currently no controlled studies investigating the 
potential effect of these activities in reducing the conversion 
rate from iRBD to PD. Therefore, these treatment options are 
not considered in the management of RBD at present.
Discussion
The current identification of sleep-related abnormalities and 
the possible relation to neurodegenerative disorders raises a 
significant number of research questions. One of the most 
important issues is that the current studies identifying RBD 
as a risk factor for later parkinsonian conversion are based on 
identifying and defining the population at risk. The current 
studies have identified patients in high-level neurological 
sleep clinics. It has still not been settled whether this may 
influence the potential effect on the conversion, eg, if patients 
identified in broader clinical settings with simpler methods 
influence the diagnostic pattern and prognosis. The presence 
of other factors, eg, medication, alcohol, and comorbidities, 
may also influence the risk association.
Although there are currently no drugs available to prevent 
or delay the disease process for parkinsonian conversion, any 
sensitive and specific biological markers would be important 
in the future for identifying high-risk individuals with the aim 
of managing the risk. Owing to the complex mechanism of 
wake–sleep regulation, knowledge of these mechanisms and 
abnormalities is central to our understanding of the progres-
sive nature of alpha-synucleinopathies. Owing to the early 
involvement and specific physiological pattern, identification 
of RBD and probably RSWA is crucial for the development 
and identification of biomarkers and potential development 
of disease-modifying medication and interventions.
A number of other symptoms and methods have been iden-
tified in RBD/PD, including imaging techniques, testing for 
olfactory and autonomic abnormalities, molecular techniques, 
and other sleep measures. It is likely that combinations of such 
approaches may enable patients to be stratified into specific 
risk associations that are of use in risk management.
One of the major challenges in defining those at risk is 
the potential relation between RBD (as defined by video-
confirmed evaluation of REM sleep-associated behavior and 
the presence of simultaneous RSWA) and minor episodes of 
muscle activity and RSWA. Recently, it was suggested that 
these minor episodes be identified as REM behavior events.123 
Questionnaires’ information may show up intra- and inter-
individual variations.124 Current prospective studies and most 
of the comorbidity studies rely on the classic definition of 
video-confirmed RBD. The extent to which dream content 
influences the diagnostic value of RBD is not known, but it 
may reflect the extent of pathology in the brainstem. Recent 
studies of day-to-day variation suggest that not only sleep 
patterns but also motor activity varies between the recorded 
days. NREM motor phenomena in patients with RBD are not 
taken into consideration,125 and in many patients with advanced 
neurodegenerative diseases, the EEG shows major abnormali-
ties, with slowing, pathological microevents (eg, K-complexes, 
sleep spindles). As a consequence, sleep scoring is often dif-
ficult and subject to significant interscorer variability.126
PD, DLB, and MSA are complex neurodegenerative dis-
orders, and their progress, severity, and symptom profile vary 
greatly between patients. It is not fully established whether 
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iRBD is a precursor of only one PD subgroup. In analyzing 
iRBD patients with the aim of identifying those at the highest 
risk of developing PD, it might be unrealistic to expect that a single 
biomarker will be sufficient. By combining multiple biomarkers, 
the sensitivity of identifying a person with preclinical PD will 
increase, due to the fact that more aspects of this complex disease 
will be revealed. Optimally, a combination of biomarkers express-
ing alterations in different areas or mechanisms of the brain would 
indicate the stage of the disease and the pace and direction in which 
it is progressing. This would not only help identify the patients at 
the highest risk of developing PD, and thereby possibly facilitate 
PD treatment before PD diagnosis, but also provide insight into 
treatment efficiency and thereby help personalized treatment.
We believe that several additional research questions need 
to be addressed in order to understand brainstem involvement 
and the associated physiological, imaging, and molecular 
findings. This is fundamental to our understanding of how 
to identify high-risk individuals and to the development of 
risk-reducing agents, including protective medication, for 
these devastating diseases.
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